Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND…

Principal Investigator: Lele, Shashikant B

A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Principal Investigator: Griffiths, Elizabeth A

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant

Principal Investigator: Chen, George L

A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(A031701) A PHASE II STUDY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS

Principal Investigator: Levine, Ellis G

A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

Principal Investigator: Griffiths, Elizabeth A

EA2176 A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients

Principal Investigator: Mukherjee, Sarbajit

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Principal Investigator: Singh, Anurag K

(A031702) Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Principal Investigator: Levine, Ellis G

(S1826) A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (NCT03907488)

Principal Investigator: Kelly, Kara M

Treatment practices and outcomes of adults with therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia related changes

Principal Investigator: Przespolewski, Amanda C

(S2000) A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

Principal Investigator: Puzanov, Igor

(NCI 9673) Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Amendment)

Principal Investigator: Mukherjee, Sarbajit

(EA2165) A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Principal Investigator: Mukherjee, Sarbajit

Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib

Principal Investigator: Fountzilas, Christos

(ALTE2031) StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

Principal Investigator: Rokitka, Denise A

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies

Principal Investigator: McCarthy, Philip L

NRG HN006:RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER

Principal Investigator: McSpadden, Ryan P

(MCC-20320) Blood based biomarkers for minimal residual disease detection in pediatric sarcomas

Principal Investigator: Gupta, Ajay

DF6002-001: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Nivolumab in…

Principal Investigator: Fountzilas, Christos

NRG-GY022, Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin (NCT# 03997370)

Principal Investigator: Lele, Shashikant B

EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer NSCLC)

Principal Investigator: Chen, Hongbin

(ARST1921) A Safety, Pharmacokinetic and Efficacy Study of a gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375),in Children and Adolescents with progressive, Surgically Unresectable Desmoid Tumors

Principal Investigator: Twist, Clare J

Phase IB/II Study of Enzalutamide with Ribociclib in Patients with Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer that retains RB Expression

Principal Investigator: Chatta, Gurkamal S

A Randomized, Multi-Center Phase 2 Trial with a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy versus SoC Therapy alone for the Treatment of Patients with Locally Advanced or Recurrent…

Principal Investigator: Wooten, Kimberly E